RDD Pharma gets $7.2M for anal delivery tech; Nanodelivery could boost fight against HIV/AIDS;

 @DamianFierce: Harvard docs say nanotreatments can clear blocked arteries with 1/50th the drug amount of standard techs. Report | Follow @DamianFierce

> Israel's RDD Pharma pulled in a $7.2 million financing round to fund the development of its anal delivery tech, designed to administer treatments for fissures and incontinence related to spinal injury. News

> In an interview with News Medical, Johns Hopkins professor and HIV/AIDS expert Charles Flexner explains that nanoparticles could be hugely beneficial in the global fight against the virus, allowing for targeted delivery of small drug amounts. More

> Echo Therapeutics ($ECTE) has expanded its licensing deal with Ferndale Pharma, allowing the company to sell a dermal anesthetic using Echo's Prelude transdermal delivery tech around the world. Release

> Alnylam Pharmaceuticals ($ALNY) is touting positive proof-of-concept data for its RNAi therapy that targets hemophilia. Story

> German researchers have discovered a new way to manufacture microspheres that they say will make it easier to get nanotreatments to their targets. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.